Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.56 |
| ▸ | PPARG | P37231 | 5/20 | 0.53 |
| ▸ | PPARA | Q07869 | 5/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979145 | 0.86 | KDM4E (0.65) | KDM4EKDRHPGDRAB9ANPC1 | |
| SCHEMBL4925692 | 0.86 | TP53 (0.52) | KDM4EHPGDRAB9ANPC1LMNA | |
| SCHEMBL5385072 | 0.84 | KDM4E (0.50) | KDM4EKDRHPGDRAB9ANPC1 | |
| SCHEMBL266619 | 0.84 | KDM4E (0.66) | KDM4EKDRHPGDRAB9ANPC1 | |
| SCHEMBL30193563 | 0.83 | KDM4E (0.61) | KDM4EKDRHPGDRAB9ANPC1 | |
| SCHEMBL30193355 | 0.83 | KDM4E (0.61) | KDM4EKDRHPGDRAB9ANPC1 | |
| SCHEMBL4888378 | 0.83 | RAB9A (0.62) | KDM4EKDRHPGDRAB9ANPC1 | |
| SCHEMBL5022312 | 0.83 | KDM4E (0.61) | KDM4EKDRHPGDRAB9ANPC1 | |
| SCHEMBL30193983 | 0.83 | KDM4E (0.61) | KDM4EKDRHPGDRAB9ANPC1 | |
| SCHEMBL13767787 | 0.83 | MAPT (0.52) | KDM4EKDRHPGDRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402883-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | ARRAKIS THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | ARRAKIS THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1357115-B1 | ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2009-06-17 | — | — | EP | disclosed |
| US-20090054435-A1 | Phenoxyalkanoic Acid Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7452907-B2 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-20080207685-A1 | Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar | ELI LILLY AND COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207685-A1 | Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar | ELI LILLY AND COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207685-A1 | Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar | ELI LILLY AND COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080146631-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | BROOKS DAWN ALISA | 2008-06-19 | — | — | US | disclosed |
| US-5932601-A | USEFUL FOR LOWERING BLOOD SUGAR AND LIPID IN BLOOD | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-08-03 | — | — | US | disclosed |
| US-5591862-A | ANTILIPEMICS, TREATING DIABETES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-01-07 | — | — | US | disclosed |
| CN-1129698-A | Oxazolidinedione derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1996-08-28 | — | — | CN | disclosed |
| CN-1124246-A | Tetrazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1996-06-12 | — | — | CN | disclosed |
| EP-0710659-A1 | Oxazolidinedione derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-05-08 | — | — | EP | disclosed |
| EP-0629624-A1 | Tetrazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-12-21 | — | — | EP | disclosed |
| US-5330998-A | Anticholesterol agents | PFIZER INC. (US) | 1994-07-19 | — | — | US | disclosed |
| EP-0389699-B1 | Thiazolidinedione derivatives as hypoglycemic agents | PFIZER (US) | 1994-05-11 | — | — | EP | disclosed |
| EP-0389699-A1 | Thiazolidinedione derivatives as hypoglycemic agents | PFIZER INC. (US) | 1990-10-03 | — | — | EP | disclosed |
| WO-1989008652-A1 | THIAZOLIDINEDIONE DERIVATIVES AS HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1989-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | NSUN3, NSUN2, POLRMT | KDM4E 1266/4885KDR 4674/4885HPGD 4386/4885 |
| US-20080146631-A1 | OXAZOLYL-ARYLOXYACETIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | PPARA, PPARG, PPARD | KDM4E 2738/4885KDR 1382/4885HPGD 1113/4885 |
| US-20080207685-A1 | Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar | PPARG, PPARD, PPARA | KDM4E 4016/4885KDR 2423/4885HPGD 132/4885 |
| US-20220402883-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | NSUN3, NSUN2, METTL16 | KDM4E 1087/4885KDR 4837/4885HPGD 4313/4885 |
| US-20090054435-A1 | Phenoxyalkanoic Acid Compound | PNLIP, GPR119, LIPC | KDM4E 310/4885KDR 2450/4885HPGD 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.